Abbott Laboratories Q1 2026 Sales and Guidance Refocus on Fair Value
Abbott Laboratories reported Q1 2026 sales of $11.16 billion, with strong contributions from medical devices, and issued full-year guidance for mid single-digit comparable sales growth. The stock gained 5.62% over 7 days but remains down 22.83% year-to-date.
Key Numbers
Abbott Laboratories (ABT) reported first-quarter 2026 sales of $11.16 billion, with solid contributions from its Medical Devices segment. The company also issued full-year guidance pointing to mid single-digit comparable sales growth. Shares have picked up short-term momentum, with a 7-day return of 5.62% and a 30-day return of 5.24%, though they remain down 22.83% year-to-date.
Key Financial Results
| Metric | Value |
|---|---|
| Q1 2026 Revenue | $11.16 billion |
| Medical Devices Contribution | Strong (exact figure not disclosed) |
| 7-Day Share Price Return | +5.62% |
| 30-Day Share Price Return | +5.24% |
| Year-to-Date Return | -22.83% |
| 1-Year Total Return | Not available |
Key Highlights from the Release
The company highlighted that Medical Devices was the primary growth driver in Q1, but did not provide detailed earnings or EPS figures.
Future Guidance
For full-year 2026, Abbott expects mid single-digit comparable sales growth, which refocuses attention on the stock's fair value.
Impact on the Stock
Despite a significant YTD decline, short-term momentum is positive, with the stock rising over 5% in the past week. This may reflect investor optimism about the guidance and medical device performance.
What This Means for Investors
The Q1 results and moderate growth guidance present a balanced picture for Abbott. Investors should monitor the continued momentum in medical devices and the company's ability to improve margins amid economic headwinds.
Frequently Asked Questions
Found this useful? Share it